An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click here to read our scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.

Total number of cases reported

Summary data from PsoProtect’s first 1525 cases.

Cases reported by country of assessment (≥20 cases):
Country Cases
United Kingdom 426
France 252
Italy 161
Spain 138
Netherlands 113
Portugal 69
United States 48
Hungary 51
Poland 61
Argentina 29
Belgium 23
Rest of the world 154

Average age: 49 years
Phenotype of psoriasis: 1483 plaque psoriasis, 42 pustular psoriasis
Average BMI: 27.8 kg/m2
Average number of days of symptoms from COVID-19: 10 days

Confirmed COVID-19:


Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Biologic – TNF inhibitor 359
Biologic – IL-23 inhibitor 402
Biologic – IL-17 inhibitor 228
Conventional systemic agent 186
Small molecule inhibitor 53
Biologic and conventional systemic co-therapy 46
Small molecule inhibitor and conventional systemic co-therapy 5
No systemic agent 242
Unknown (participating in clinical trial) 4

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Outcome of COVID-19: